Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291784 · ClinicalTrials.gov registry record · Phase 1
Anti-TGF-beta Therapy in Patients With Myelofibrosis
A Phase 1 study, sponsored by John Mascarenhas.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01291784 is a Phase 1 study that was terminated before completion, run by John Mascarenhas. The registered enrollment target is 3 participants.
The verdict
NCT01291784, a Phase 1 study, was terminated before completion, sponsored by John Mascarenhas.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation. This is a novel approach to the treatment of patients with myelofibrosis.
Interventions
- BIOLOGICAL monoclonal antibody to TGF-beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291784
The ClinicalTrials.gov registry entry for NCT01291784 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody to TGF-beta is the first listed.
NCT01291784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01291784 about?
NCT01291784 is a clinical study titled "Anti-TGF-beta Therapy in Patients With Myelofibrosis". TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The investigators propose that inhibiting the...
What is the current status of trial NCT01291784?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-02. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01291784?
The interventions under investigation include: monoclonal antibody to TGF-beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT01291784?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.